BR112022013322A2 - Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina - Google Patents
Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicinaInfo
- Publication number
- BR112022013322A2 BR112022013322A2 BR112022013322A BR112022013322A BR112022013322A2 BR 112022013322 A2 BR112022013322 A2 BR 112022013322A2 BR 112022013322 A BR112022013322 A BR 112022013322A BR 112022013322 A BR112022013322 A BR 112022013322A BR 112022013322 A2 BR112022013322 A2 BR 112022013322A2
- Authority
- BR
- Brazil
- Prior art keywords
- tricyclic
- medicine
- preparation
- application
- tetrahydroisoquinoline derivative
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010025118 | 2020-01-10 | ||
| CN202010036802 | 2020-01-14 | ||
| CN202010273891 | 2020-04-09 | ||
| CN202010680491 | 2020-07-15 | ||
| CN202010819555 | 2020-08-14 | ||
| CN202010971693 | 2020-09-16 | ||
| PCT/CN2021/070826 WO2021139756A1 (zh) | 2020-01-10 | 2021-01-08 | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013322A2 true BR112022013322A2 (pt) | 2022-09-20 |
Family
ID=76787742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013322A BR112022013322A2 (pt) | 2020-01-10 | 2021-01-08 | Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12428428B2 (enExample) |
| EP (1) | EP4089094A4 (enExample) |
| JP (1) | JP7657807B2 (enExample) |
| KR (1) | KR20220125272A (enExample) |
| CN (2) | CN114746424B (enExample) |
| AU (1) | AU2021205156B2 (enExample) |
| BR (1) | BR112022013322A2 (enExample) |
| CA (1) | CA3164166A1 (enExample) |
| MX (1) | MX2022008091A (enExample) |
| TW (1) | TWI882060B (enExample) |
| WO (1) | WO2021139756A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021205156B2 (en) | 2020-01-10 | 2026-07-02 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
| CN117642405B (zh) * | 2021-07-09 | 2026-05-12 | 江苏恒瑞医药股份有限公司 | 一种三环四氢异喹啉类衍生物的盐型 |
| CN117813288A (zh) | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
| JP2025529974A (ja) | 2022-09-09 | 2025-09-09 | サノフイ | 置換テトラヒドロシクロヘプタ［ｅ］インドール誘導体、それらの調製のプロセス及びその治療的使用 |
| WO2025209455A1 (zh) * | 2024-04-01 | 2025-10-09 | 山东盛迪医药有限公司 | 一种选择性雌激素受体降解剂的制备方法 |
| WO2026086864A1 (zh) * | 2024-10-24 | 2026-04-30 | 江苏恒瑞医药股份有限公司 | 一种kat6抑制剂的联合使用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
| WO2013073875A1 (ko) | 2011-11-15 | 2013-05-23 | 한국화학연구원 | 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법 |
| EP2941421A4 (en) | 2013-01-07 | 2016-09-21 | Bg Negev Technologies & Applic Ltd | COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| WO2014141292A2 (en) | 2013-03-04 | 2014-09-18 | Intas Pharmaceuticals Limited | Endoxifen citrate polymorph and process for preparing the same |
| IN2013MU00665A (enExample) | 2013-03-05 | 2015-07-03 | Cipla Ltd | |
| CN105121413B (zh) | 2013-03-14 | 2018-09-14 | 赛拉根医药股份有限公司 | 多环雌激素受体调节剂及其用途 |
| EP2981530B1 (en) | 2013-04-04 | 2020-02-12 | The Administrators of the Tulane Educational Fund | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells |
| AP2015008858A0 (en) | 2013-05-28 | 2015-11-30 | Astrazeneca Ab | Chemical compounds |
| WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| EP3312184A4 (en) * | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
| EP3328999B1 (en) | 2015-07-30 | 2020-03-25 | Arcis Biotechnology Holdings Limited | Method using a quaternary ammonium compound |
| EP3440067B1 (en) * | 2016-04-08 | 2021-05-26 | F. Hoffmann-La Roche AG | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| CA3082276C (en) * | 2017-11-14 | 2022-08-16 | Anlin Pharmaceuticals, Llc | Heterocyclic compounds and their application in medicine |
| CN111770924B (zh) * | 2018-04-04 | 2023-05-09 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| WO2019228443A1 (en) | 2018-05-30 | 2019-12-05 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Selective estrogen receptor downregulators and uses thereof |
| AU2021205156B2 (en) | 2020-01-10 | 2026-07-02 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
-
2021
- 2021-01-08 AU AU2021205156A patent/AU2021205156B2/en active Active
- 2021-01-08 TW TW110100844A patent/TWI882060B/zh active
- 2021-01-08 CA CA3164166A patent/CA3164166A1/en active Pending
- 2021-01-08 JP JP2022540980A patent/JP7657807B2/ja active Active
- 2021-01-08 CN CN202180006879.9A patent/CN114746424B/zh active Active
- 2021-01-08 BR BR112022013322A patent/BR112022013322A2/pt unknown
- 2021-01-08 WO PCT/CN2021/070826 patent/WO2021139756A1/zh not_active Ceased
- 2021-01-08 KR KR1020227026103A patent/KR20220125272A/ko active Pending
- 2021-01-08 US US17/790,110 patent/US12428428B2/en active Active
- 2021-01-08 EP EP21738824.8A patent/EP4089094A4/en active Pending
- 2021-01-08 CN CN202310574384.7A patent/CN116731064B/zh active Active
- 2021-01-08 MX MX2022008091A patent/MX2022008091A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230140679A1 (en) | 2023-05-04 |
| CN114746424B (zh) | 2023-06-16 |
| AU2021205156A1 (en) | 2022-07-14 |
| CN114746424A (zh) | 2022-07-12 |
| JP2023509944A (ja) | 2023-03-10 |
| US12428428B2 (en) | 2025-09-30 |
| TW202140495A (zh) | 2021-11-01 |
| CN116731064A (zh) | 2023-09-12 |
| TWI882060B (zh) | 2025-05-01 |
| EP4089094A1 (en) | 2022-11-16 |
| AU2021205156B2 (en) | 2026-07-02 |
| CN116731064B (zh) | 2026-06-16 |
| CA3164166A1 (en) | 2021-07-15 |
| WO2021139756A1 (zh) | 2021-07-15 |
| KR20220125272A (ko) | 2022-09-14 |
| EP4089094A4 (en) | 2023-08-02 |
| JP7657807B2 (ja) | 2025-04-07 |
| MX2022008091A (es) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
| BR112023019967A2 (pt) | Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina | |
| BR112022014398A2 (pt) | Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| MX2022008091A (es) | Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| BR112018075734A2 (pt) | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. | |
| BR112018011817A2 (pt) | derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX372914B (es) | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. | |
| BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| BR112018007876A2 (pt) | derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina | |
| BR112015022566A2 (pt) | composto e composição farmacêutica | |
| BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
| JOP20180025A1 (ar) | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| BR112022023983A2 (pt) | Compostos terapêuticos | |
| BR112021024546A2 (pt) | Compostos tricíclicos e uso dos mesmos | |
| UY33470A (es) | Derivados de 6,7-dihidro-5h-benzo[7]anulenos, métodos para su preparación, preparaciones farmacéuticas que los contienen y su uso para la preparación de medicamentos | |
| BR112021017415A2 (pt) | Derivados de pirimidona de anel fundido para uso no tratamento de infecção por vhb ou de doenças induzidas por vhb | |
| BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
| BR112022010360A2 (pt) | Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos | |
| BR112022016432A2 (pt) | Compostos heterocíclicos de heteroarila e usos dos mesmos |